+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06409832

Rimegepant as a Preventive Treatment for Episodic Migraine A Multicenter Prospective Study

Led by University of Florence · Updated on 2026-06-11

100

Participants Needed

2

Research Sites

34 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate how well rimegepant works and how well patients tolerate it when used as a preventive treatment for people with episodic or chronic migraine. Rimegepant is a new type of small molecule that blocks the calcitonin gene-related peptide CGRP receptor, available as a 75 mg orally disintegrating tablet. Previous trials showed its potential in preventing migraines and its tolerability, with common side effects like nausea and infections. Participants will take rimegepant 75 mg every other day for up to two years, depending on reimbursement approval. This study is prospective and multicentric, enrolling patients who meet specific criteria and collecting baseline demographic and clinical information. Data are gathered at baseline and every three months during the two-year observation period. During the study, participants will keep a headache diary recording monthly headache and migraine days, migraine severity, related symptoms, and medication use. Researchers will collect questionnaires and monitor demographic data, migraine history, pain intensity, associated symptoms, disability, side effects, treatment persistence, and quality of life through an online database. The main outcomes include changes in migraine frequency and the percentage of patients with at least a 50% reduction in monthly migraine days after three months of treatment.

CONDITIONS

Brief Title

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Research Team

L

Luigi F Iannone, MD

R

Roberto De Icco, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here